Search
for
Sort by
Research 30 of 37
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
- GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação
- Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
- Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
- GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
- Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Exploring Herbal Alternatives to Pharmaceutical Treatments for Polycystic Ovary Syndrome
- Ayurveda & Bioactives as Adjuvant for Dna Modulation in Cancer Treatment & Adverse Drug Reaction [ADR] – A Glimpse of Traditional Indian Nanotechnology
- Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Endocrinologia e Medicina Estética Ed. X
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
- Dermatological, Trichological and Quality of Life Consequences of GLP ‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey
- Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
- Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database